ALLMedicine™ Pancreatic Cancer Center

Feb 27th, 2021 - Mesothelin is a 40-kDa glycoprotein that is highly overexpressed in various types of cancers, however molecular mechanism of mesothelin has not been well-known. Amatuximab is a chimeric monoclonal IgG1/k antibody targeting mesothelin. We recently ...

Feb 26th, 2021 - The association between cancer and venous thromboembolism (VTE) has been established for more than 150 years. Nevertheless, cancer-associated thrombosis still remains a major clinical challenge and is associated with significant morbidity and mort...

Feb 26th, 2021 - Poultry plant workers are exposed to chemical carcinogens and oncogenic viruses in their work environment. Our objective was to identify jobs and workplaces related to poultries that could increase the pancreatic cancer risk. We conducted a case-c...

Feb 26th, 2021 - This study shows that pancreatic cancer cells undergoing cell death by Valproic Acid (VPA) treatment activated DCs more efficiently than those treated with Trichostatin A (TSA), as demonstrated by CD86 and CD80 surface expression. Surprisingly tho...

Feb 25th, 2021 - Although the efficacy of neoadjuvant therapies for pancreatic cancer (PDAC) is reported in recent years, ideal neoadjuvant treatment for patients with potentially resectable (R) PDAC remains uncertain. We conducted the retrospective study about th...

Mar 6th, 2020 - Clinical Practice Guidelines for Pancreatic Cancer were first published in 2006 by the Japan Pancreas Society, and they were revised in 2009, 2013, and 2016. In July 2019, the Clinical Practice Guidelines for Pancreatic Cancer 2019 were newly revi...

Sep 2nd, 2019 - This guideline systematically reviews the evidence for treatment of pancreatic cancer with radiation in the adjuvant, neoadjuvant, definitive, and palliative settings and provides recommendations on indications and technical considerations. The Am...

Aug 6th, 2019 - Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. Although its ...

Aug 5th, 2019 - Importance Pancreatic adenocarcinoma is the third most common cause of cancer death among men and women in the United States. Objective To systematically review benefits and harms of screening for pancreatic adenocarcinoma to inform the US Prev...

Aug 5th, 2019 - The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults.

Feb 27th, 2021 - Mesothelin is a 40-kDa glycoprotein that is highly overexpressed in various types of cancers, however molecular mechanism of mesothelin has not been well-known. Amatuximab is a chimeric monoclonal IgG1/k antibody targeting mesothelin. We recently ...

Feb 26th, 2021 - The association between cancer and venous thromboembolism (VTE) has been established for more than 150 years. Nevertheless, cancer-associated thrombosis still remains a major clinical challenge and is associated with significant morbidity and mort...

Feb 26th, 2021 - Poultry plant workers are exposed to chemical carcinogens and oncogenic viruses in their work environment. Our objective was to identify jobs and workplaces related to poultries that could increase the pancreatic cancer risk. We conducted a case-c...

Feb 26th, 2021 - This study shows that pancreatic cancer cells undergoing cell death by Valproic Acid (VPA) treatment activated DCs more efficiently than those treated with Trichostatin A (TSA), as demonstrated by CD86 and CD80 surface expression. Surprisingly tho...

Feb 25th, 2021 - Although the efficacy of neoadjuvant therapies for pancreatic cancer (PDAC) is reported in recent years, ideal neoadjuvant treatment for patients with potentially resectable (R) PDAC remains uncertain. We conducted the retrospective study about th...

Feb 22nd, 2021 - Cancer death rates overall continue to fall among both men and women in Europe, with the notable exception of pancreatic cancer in both sexes and lung cancer among women living in the European Union, notes an update report. "Among the major cancer...

Jan 25th, 2021 - Pancreatic enzyme replacement therapy (PERT) is often an essential component of the treatment regimen for patients with pancreatic cancer, but it can be very pricey. "Out-of-pocket costs for a 30-day supply of enzymes for Medicare beneficiaries ca...

Jan 19th, 2021 - Patients with borderline resectable pancreatic cancer (PDAC) are often treated with chemotherapy, radiotherapy, or both before undergoing surgery, but the optimal regimen in this setting is controversial. New results suggest that the reference reg...

Dec 3rd, 2020 - A simple blood test, claimed to detect more than 50 types of cancer, will be used in a pilot trial by National Health Service (NHS) England in a bid to increase rates of early-stage diagnosis, in particular for cancers that are currently difficult...

Nov 18th, 2020 - The PARP inhibitor olaparib (Lynparza) has been shown to delay progression  in patients with metastatic pancreatic cancer who harbor BRCA 1/2 mutations, and is now approved for this indication. A new study suggests that this approach can be cost-e...